Accelerate Diagnostics Profit Margin

Accelerate Diagnostics (AXDX) currently reports a profit margin of -427.82% as of December 2024. That compares with -465.56% in the prior-year period — up 8.1% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Accelerate Diagnostics's profit margin history and peer comparisons.

Accelerate Diagnostics's profit margin increased from -465.56% to -427.82% — a 8.1% year-over-year increase (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Accelerate Diagnostics's profit margin of -427.82% is lower than the Healthcare sector average of 14.34%. That is roughly 3082.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Accelerate Diagnostics's current -427.82% should be judged against Healthcare norms (sector average: 14.34%) and against AXDX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -427.82%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Accelerate Diagnostics, and consider following AXDX for alerts when major investors trade the stock.